TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions

Stock Information for TFF Pharmaceuticals Inc - Ordinary Shares

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About TFF Pharmaceuticals Inc - Ordinary Shares

TFF Pharmaceuticals Announces Closing of Pricing of $4.8 Million Public Offering
TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering
TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT Annual Meeting
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs
TFF Pharmaceuticals Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
TFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
TFF Pharmaceuticals Announces Update on Clinical Programs

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.